Emcure Pharmaceuticals Pivot Points
- Market cap
- ₹36,312 crore
- P/E
- 35.9
- P/B
- 7.34
- ROE
- 19.7%
- Dividend yield
- 0.19%
Based on the 7 October 2026 session (high ₹1,944.03, low ₹1,886.57, close ₹1,915.30), the classic daily pivot for Emcure Pharmaceuticals is ₹1,915.30, with first resistance at ₹1,944.03 and first support at ₹1,886.57. The central pivot range runs from ₹1,915.30 to ₹1,915.30, 0.00% wide.
Period used for each timeframe
| Timeframe | Period | High | Low | Close |
|---|---|---|---|---|
| Daily | 7 Oct 2026 | 1,944.03 | 1,886.57 | 1,915.30 |
| Weekly | 7 Oct 2026 – 7 Oct 2026 | 1,982.34 | 1,848.26 | 1,915.30 |
| Monthly | 7 Oct 2026 – 7 Oct 2026 | 2,058.95 | 1,771.65 | 1,915.30 |
Classic pivot points
| Level | Daily | Weekly | Monthly |
|---|---|---|---|
| R3 | 2,001.49 | 2,116.42 | 2,346.25 |
| R2 | 1,972.76 | 2,049.38 | 2,202.60 |
| R1 | 1,944.03 | 1,982.34 | 2,058.95 |
| Pivot | 1,915.30 | 1,915.30 | 1,915.30 |
| S1 | 1,886.57 | 1,848.26 | 1,771.65 |
| S2 | 1,857.84 | 1,781.22 | 1,628.00 |
| S3 | 1,829.11 | 1,714.18 | 1,484.35 |
Fibonacci pivot points
| Level | Daily | Weekly | Monthly |
|---|---|---|---|
| R3 | 1,972.76 | 2,049.38 | 2,202.60 |
| R2 | 1,950.81 | 1,998.16 | 2,092.85 |
| R1 | 1,937.25 | 1,966.52 | 2,025.05 |
| Pivot | 1,915.30 | 1,915.30 | 1,915.30 |
| S1 | 1,893.35 | 1,864.08 | 1,805.55 |
| S2 | 1,879.79 | 1,832.44 | 1,737.75 |
| S3 | 1,857.84 | 1,781.22 | 1,628.00 |
Camarilla pivot points
| Level | Daily | Weekly | Monthly |
|---|---|---|---|
| R4 | 1,946.90 | 1,989.04 | 2,073.31 |
| R3 | 1,931.10 | 1,952.17 | 1,994.31 |
| R2 | 1,925.83 | 1,939.88 | 1,967.97 |
| R1 | 1,920.57 | 1,927.59 | 1,941.64 |
| Pivot | 1,915.30 | 1,915.30 | 1,915.30 |
| S1 | 1,910.03 | 1,903.01 | 1,888.96 |
| S2 | 1,904.77 | 1,890.72 | 1,862.63 |
| S3 | 1,899.50 | 1,878.43 | 1,836.29 |
| S4 | 1,883.70 | 1,841.56 | 1,757.29 |
Woodie pivot points
| Level | Daily | Weekly | Monthly |
|---|---|---|---|
| R3 | 2,001.49 | 2,116.42 | 2,346.25 |
| R2 | 1,972.76 | 2,049.38 | 2,202.60 |
| R1 | 1,944.03 | 1,982.34 | 2,058.95 |
| Pivot | 1,915.30 | 1,915.30 | 1,915.30 |
| S1 | 1,886.57 | 1,848.26 | 1,771.65 |
| S2 | 1,857.84 | 1,781.22 | 1,628.00 |
| S3 | 1,829.11 | 1,714.18 | 1,484.35 |
Central pivot range (CPR)
| Timeframe | Top (TC) | Pivot | Bottom (BC) | Width |
|---|---|---|---|---|
| Daily | 1,915.30 | 1,915.30 | 1,915.30 | 0.00% |
| Weekly | 1,915.30 | 1,915.30 | 1,915.30 | 0.00% |
| Monthly | 1,915.30 | 1,915.30 | 1,915.30 | 0.00% |
Source: Calculated by ATS from NSE end-of-day high, low and close prices. Data as of 7 October 2026. How this data is compiled.
Emcure Pharmaceuticals pivot points — frequently asked questions
What is the Emcure Pharmaceuticals pivot point today?
The classic daily pivot point for Emcure Pharmaceuticals (EMCURE) is ₹1,915.30, calculated from the 7 October 2026 session's high, low and close. It applies to the next trading session.
What are the support and resistance levels for Emcure Pharmaceuticals?
Classic daily levels: resistance at ₹1,944.03 (R1), ₹1,972.76 (R2) and ₹2,001.49 (R3); support at ₹1,886.57 (S1), ₹1,857.84 (S2) and ₹1,829.11 (S3). Fibonacci, Camarilla and Woodie levels are in the tables above.
What is the Emcure Pharmaceuticals weekly pivot?
The classic weekly pivot is ₹1,915.30, from the week of 7 Oct 2026 to 7 Oct 2026, with weekly resistance at ₹1,982.34 and support at ₹1,848.26.
How are pivot points calculated?
The classic pivot is the average of the previous period's high, low and close: PP = (H + L + C) / 3. Resistance R1 = 2 × PP − L and support S1 = 2 × PP − H; R2 and S2 add or subtract the high-low range. Fibonacci levels apply 38.2%, 61.8% and 100% of the range to the pivot, Camarilla levels are built around the close, and Woodie weights the close twice.
Same Data For Peers
Trade Emcure Pharmaceuticals With ATS
Track EMCURE live and place orders from the Pocket app or the Pocket Web terminal with an ATS trading and demat account.
Figures are for information only and are not investment advice or a recommendation to buy, sell or hold any security. Investments in securities are subject to market risks; read all related documents carefully before investing.